PharmaCyte Biotech, Inc. (PMCB)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Currency in USD
Valuation measures4
| Market cap (intra-day) | 18.26M |
| Enterprise value | -25.43M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | N/A |
| Price/book (mrq) | 0.58 |
| Enterprise value/revenue | N/A |
| Enterprise value/EBITDA | 6.18 |
Trading information
Stock price history
| Beta (5Y monthly) | -0.16 |
| 52-week change 3 | -23.93% |
| S&P500 52-week change 3 | 21.33% |
| 52-week high 3 | 3.2300 |
| 52-week low 3 | 1.9200 |
| 50-day moving average 3 | 2.1909 |
| 200-day moving average 3 | 2.2621 |
Share statistics
| Avg vol (3-month) 3 | 25.91k |
| Avg vol (10-day) 3 | 7.81k |
| Shares outstanding 5 | 8.45M |
| Implied shares outstanding 6 | 8.77M |
| Float 8 | 8.07M |
| % held by insiders 1 | 8.12% |
| % held by institutions 1 | 14.86% |
| Shares short (15 Apr 2024) 4 | 18.23k |
| Short ratio (15 Apr 2024) 4 | 0.34 |
| Short % of float (15 Apr 2024) 4 | 0.23% |
| Short % of shares outstanding (15 Apr 2024) 4 | 0.22% |
| Shares short (prior month 15 Mar 2024) 4 | 7.62k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:1550 |
| Last split date 3 | 12 Jul 2021 |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Apr 2023 |
| Most-recent quarter (mrq) | 31 Jan 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -5.24% |
| Return on equity (ttm) | -1.73% |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | N/A |
| Net income avi to common (ttm) | -14.82M |
| Diluted EPS (ttm) | -1.4800 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 61.21M |
| Total cash per share (mrq) | 7.23 |
| Total debt (mrq) | N/A |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 27.34 |
| Book value per share (mrq) | 3.68 |
Cash flow statement
| Operating cash flow (ttm) | -2.11M |
| Levered free cash flow (ttm) | -1.93M |
© 2024 Yahoo. All rights reserved.